Bris­tol My­ers posts an­oth­er win for their Ote­zla com­peti­tor, this time with PhII da­ta in pso­ri­at­ic arthri­tis

Less than a week af­ter claim­ing a Phase III vic­to­ry over Am­gen’s Ote­zla in pso­ri­a­sis, Bris­tol My­ers Squibb has more pos­i­tive da­ta out in pso­ri­at­ic arthri­tis.

The Phase II read­out for the TYK2 con­tender deu­cravac­i­tinib (BMS-986165), which BMS an­nounced Mon­day, showed the ex­per­i­men­tal drug met its pri­ma­ry end­point of re­duc­ing symp­toms by at least 20 per­cent af­ter 16 weeks. BMS mea­sured two dosage lev­els for the once-a-day pill, 6 mg and 12 mg, with both out­per­form­ing the place­bo group.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER